Select Page
Skip to main content
Documentation
Categories
< All Topics
Print

Schedule Y – Requirements and Historical Role in Clinical Trials

Updated

Schedule Y of the Drugs and Cosmetics Rules, 1945 has historically been an important component of India’s regulatory framework for new drugs and clinical trials.

It established requirements relating to clinical development, clinical-trial conduct and the information required for the approval of new drugs in India.

Major Areas Covered by Schedule Y

Schedule Y addressed important aspects of clinical research including:

  • Requirements and guidelines for clinical trials
  • Clinical development of new drugs
  • Responsibilities of sponsors
  • Responsibilities of investigators
  • Responsibilities of ethics committees
  • Informed consent and protection of trial participants
  • Safety and adverse-event reporting
  • Clinical trials involving special populations
  • Post-marketing surveillance and special studies
  • Data and documentation required for new drug applications

Its appendices also provided detailed requirements and formats relating to clinical-trial and new-drug submissions.

Role in Indian Clinical Research

Schedule Y contributed significantly to the development of Good Clinical Practice and regulatory oversight of clinical trials in India. Its provisions helped establish expectations for scientific validity, ethical conduct, participant protection and regulatory documentation.

For this reason, Schedule Y remains an important subject when studying the development and history of Indian clinical-trial regulation.

Current Position

The regulatory framework has evolved substantially since Schedule Y was introduced.

The New Drugs and Clinical Trials Rules, 2019 (NDCTR 2019) now provide the principal regulatory framework for new drugs, investigational new drugs, clinical trials, bioavailability and bioequivalence studies, and associated ethics committee requirements covered by the Rules.

Schedule Y should therefore be understood within its historical regulatory context rather than presented as the complete current framework for clinical trials in India.

Clinical research professionals should refer to the current version of the NDCTR 2019, subsequent amendments and applicable CDSCO requirements when determining present regulatory obligations.

You may be interested in the programs below: